"With 40% of our revenues now in Part D, Omnicare represents one of the more direct investments in Medicare Part D." That is how Omnicare Inc. CEO Joel Gemunder prefaced a discussion of the new drug benefit program during an appearance by the long-term care pharmacy provider at the Goldman Sachs health care conference June 15.
On one level, Gemunder’s description of the company is a simple acknowledgement of the realities facing investors in the stock....






